Mercom Capital Group LLC is a global communications consulting firm that recently launched its 2014 annual report on financing and M&A in healthcare information technology, covering transactions of all sizes around the world. According to the report, in 2014, the global medical and health information technology venture capital record broke again, reaching 4.7 billion US dollars, more than double the 2013. The author also compiled this report: Compared with 571 US$2.2 billion in 2013, transactions in the medical and health information technology sector increased to 670 in 2014, and wind investment funds more than doubled to US$4.7 billion. The sector also brought in $2.1 billion in debt and open market financing, including six IPOs (initial public offerings), bringing total corporate finance to nearly $7 billion in this area. In addition, compared with the 212 transactions in the third quarter, compared with 956 million US dollars, the wind investment in the fourth quarter of 14 years increased to 134 transactions, 1.2 billion US dollars. “2014 is another year of amazing fund-raising in the field of medical and health information technology. We have been tracking data for five years. This area has raised a total of 8.8 billion dollars in wind investment funds and 3.6 billion dollars in open market and debt financing. A total of $12.4 billion - largely driven by the high-tech and affordable medical bills. But when you see the market performance of companies taking IPO routes in 2014, they will feel that the VC group has shown The enthusiasm in the field is not very compatible with this open market,†commented Raj Prabhu, CEO and co-founder of Mercom Capital Group. In 2014, 234 transactions were conducted in practice-centric companies, raising $2.4 billion, including $517 million for clinical decision support companies, $367 million for data analysis companies, and $247 million for population health management companies. Consumer-centric companies raised $2.3 billion and reached 436 deals. Internet health (mHealth) is the largest investment in venture capital, bringing in $1.2 billion, of which most of the money goes to wearable and mobile medical applications in Internet healthcare, at 526 million and 507 million, respectively. . Telemedicine and comparative shopping also received $369 million and $288 million, respectively. Significant growth in the technical field: · Internet medical application: 341% · Telemedicine: 297% ·Comparative shopping: 216% · Data analysis: 146% · Wearable: 136% NantHealth reached two deals in the first two rounds of venture capital in 2014, raising $320 million and $135 million, Flatiron Health raised $130 million, and then Alignment Healthcare raised $125 million. Proteus Digital Health raised $120 million (they also raised $52 million in another deal, bringing them a total of $172 million in 14 years). In addition, China's registered network raised $100 million, the Dedalus Group raised $89 million, and American Well raised $81 million. Diagnostic reagents can be divided into two categories: in vivo diagnostic reagents and in vitro diagnostic reagents. It is mostly a reagent for detection by the reaction between antigen and antibody. Urine Rapid Test Kit,Rapid Test Kit 6-Panel,Toxoplasma rapid test kits,Fecal Occult Blood Test Jilin Sinoscience Technology Co. LTD , https://www.jlgkscience.com
A: Classification of in vitro diagnostic reagents:
1. In vitro biodiagnostic reagents managed as drugs include:
1. Blood type and tissue type reagents;
2. Microbial antigen, antibody and nucleic acid detection reagents;
3. Tumor marker reagents;
4. Immunohistochemistry and human tissue cell reagents;
5. Human genetic testing reagents;
6. Biochips;
7. Allergy diagnostic reagents.
2. In vitro reagents managed as medical devices include:
1. Clinical basic test reagents;
2. Clinical chemistry reagents;
3. Blood gas and electrolyte determination reagents;
4. Vitamin determination reagents;
5. Cell histochemical stains;
6. Autoimmune diagnostic reagents;
7. Microbiological test reagents.
B: According to medical test items, clinical diagnostic reagents can be roughly divided into clinical chemical test reagents, immunology and
Serological testing reagents, hematological and cytogenetic testing reagents, microbiological testing reagents, body fluid excretion
Detection reagents, genetic diagnosis reagents, etc. Among them, the market share of clinical chemistry
The largest, close to 34%; followed by the immunology market, accounting for about 29%. Novel immunodiagnostic reagents and genetic diagnostic tests
The reagent was developed in the late 1980s, and it is the most common diagnostic reagent for all current diagnostic reagents, regardless of technology or market.
The fastest growing product.
2014 global medical health information technology venture capital broke record